SARS-CoV-2_Webinar-V2-990x120

Event Overview

SARS-CoV-2 is characterized by its rapid spread and significant human-to-human transmission. With no approved vaccines or treatments yet available, researchers are exploring various medical interventions, including neutralizing monoclonal antibodies (mAbs), to control the global COVID-19 pandemic. The SARS-CoV-2 spike (S) glycoprotein, which promotes entry into host cells, is the main target of neutralizing antibodies. In this multisponsored webinar by The Scientist, a panel of researchers will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.

Topics to be covered
  • Human monoclonal antibodies for SARS-CoV-2
  • SARS-CoV-2 neutralizing antibodies for global access
Tuesday, July 28, 2020
 
2:30 - 4:00 PM, Eastern Standard Time


Speakers

Crowe.png
James E. Crowe, Jr., MD
Director, Vanderbilt Vaccine Center
Professor, Pediatrics and Pathology, Microbiology and Immunology
Ann Scott Carrell Chair

Sok.png
Devin Sok, PhD
Senior Director, Antibody Discovery and Development
IAVI


biotechne.png
biotechne.png

biotechne.png

biotechne.png

biotechne.png
10x.png


BPS.png

Register Now

TS_WEBINARSIGNUP_Putting the Brakes on SARS-CoV-2: Neutralizing Antibodies July 28, 2020

You must have Javascript and Cookies enabled to access this webcast.

Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this webinar. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these webinars free of charge for our readers.